• Ligand Pharma readies $650M convertible debt offering biospectrumasia
    May 18, 2018
    In connection with the offering of the notes, Ligand expects to grant the initial purchasers a 13-day option to purchase up to an additional $100 million aggregate principal amount of the notes, solely to cover overallotments, if any.
PharmaSources Customer Service